m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT02252
 [1], [2]
DNA methylation DNMT1 METTL14 Direct Inhibition m6A modification CXCR4 CXCR4 METTL14 Methylation : m6A sites
m6A Modification:
m6A Regulator Methyltransferase-like 14 (METTL14) WRITER
 Regulator Info 
m6A Target C-X-C chemokine receptor type 4 (CXCR4)
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type DNA methylation (DNAMeth)
Epigenetic Regulator DNA (cytosine-5)-methyltransferase 1 (DNMT1) WRITER View Details
Regulated Target Methyltransferase-like protein 14 (METTL14) View Details
Crosstalk Relationship DNA methylation  →  m6A Inhibition
Crosstalk Mechanism DNA methylation directly impacts m6A modification through modulating the expression level of m6A regulator
Crosstalk Summary lncRNA UCA1 recruited DNA methyltransferase (DNMT1, DNMT3A, and DNMT3B) to the METTL14 promoter region to inhibit METTL14 expression in breast cancer. LNC942-METTL14-C-X-C chemokine receptor type 4 (CXCR4)/CYP1B1 signaling axis, which provides new targets and crosstalk m6A epigenetic modification mechanism for breast cancer prevention and treatment.
Responsed Disease Breast cancer ICD-11: 2C60
 Disease Info 
Pathway Response Apoptosis hsa04210
Cell Process Cell apoptosis
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
C-X-C chemokine receptor type 4 (CXCR4) 61 Compound(s) Regulating the Target Click to Show/Hide the Full List
 Compound Name Plerixafor Approved [3]
Synonyms
Mozobil; AMD3100; Amd 3100; JM 2987; JM 3100; JM3100; SDZ SID 791; SID791; AMD-3100; Bicyclam JM-2987; JM-3100; Mozobil (TN); GNA & AMD-3100; HHA & AMD-3100; Plerixafor (INN/USAN); 1,1'-[1,4-Phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane]; 1,1'-[1,4-Phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane] & Galanthus nivalis agglutinin (GNA); 1,1'-[1,4-Phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane] & Hippeastrum hybrid agglutinin(HHA); 1,1'-{1,4-phenylenebis(methylene)}-bis{1,4,8,11-tetraaza-cyclotetradecane}; 1-[[4-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)phenyl]methyl]-1,4,8,11-tetrazacyclotetradecane
    Click to Show/Hide
MOA Antagonist
Activity IC50 = 0.057 ug.mL-1
External Link
CID: 65015
TTD: D0L5RW
DrugBank: DB06809
 Compound Name Motixafortide Approved [4]
MOA Antagonist
External Link
CID: 91865076
TTD: D0T6CN
DrugBank: DB14939
 Compound Name Ulocuplumab Phase 3 [5]
MOA Antagonist
External Link
TTD: D0C3LQ
 Compound Name Balixafortide Phase 3 [6]
Synonyms
1051366-32-5; Balixafortide [INN]; UNII-PRC974M49B; PRC974M49B; Ala-cys-ser-ala-pro-arg-tyr-cys-tyr-gln-lys-pro-pro-tyr-his cyclic (2->9)-disulfide; Cyclo(L-alanyl-L-cysteinyl-L-seryl-L-alanyl-D-prolyl-(2S)-2,4-diaminobutanoyl-L-arginyl-L-tyrosyl-L-cysteinyl-L-tyrosyl-L-glutaminyl-L-lysyl-D-prolyl-L-prolyl-L-tyrosyl-L-histidyl), cyclic (2->9)-disulfide
    Click to Show/Hide
MOA Antagonist
External Link
CID: 91864511
TTD: D0GG9P
 Compound Name AMD-070 Phase 3 [7]
Synonyms
AMD 070; AMD070; AMD11070; S14-0353; N-(1H-benzoimidazol-2-ylmethyl)-N-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine; N'-(1H-Benzo[d]imidazol-2-ylmethyl)-N'-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine Trihydrobromide Dihydrate
    Click to Show/Hide
MOA Antagonist
Activity IC50 = 13 nM
External Link
CID: 11256587
TTD: D0O2XQ
DrugBank: DB05501
 Compound Name TG-0054 Phase 2 [8]
Synonyms
CXCR4 binding inhibitor/cell mobilizer (iv, stem cell transplant), TaiGen Biotechnology
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 44479007
TTD: D06KGI
DrugBank: DB11970
 Compound Name POL-6326 Phase 2 [9]
Synonyms
CXCR4 antagonists, Polyphor; POL-2438; POL-3026; Epitope mimetics (HIV fusion), Polyphor; CXCR4 antagonists (cancer/HIV), Polyphor
    Click to Show/Hide
MOA Antagonist
External Link
TTD: D0FV8P
 Compound Name CTCE-9908 Phase 1/2 [10]
Synonyms
Anticancer therapy, Chemokine Therapeutics; CTCE-9908/0019
    Click to Show/Hide
MOA Modulator
External Link
CID: 16186350
TTD: D01TJM
 Compound Name USL311 Phase 1/2 [11]
Synonyms
Usl-311; UNII-2BTG5MX2Q2; 2BTG5MX2Q2; SCHEMBL15347153; 2-Pyridinecarboxamide, 6-(hexahydro-4-(1-(1-methylethyl)-4-piperidinyl)-1H-1,4-diazepin-1-yl)-N-4-pyridinyl-; 1373268-67-7
    Click to Show/Hide
MOA Antagonist
External Link
CID: 56961879
TTD: D08XQV
DrugBank: DB15265
 Compound Name ALX-0651 Phase 1 [12]
Synonyms
Anti-CXCR4 nanobodies (cancer), Ablynx
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: D09MPD
 Compound Name CTCE-0214 Phase 1 [13]
Synonyms
CTCE-0013; CTCE-0021; CXCR4 agonists, Chemokine Therapeutics; Stem cell transplant therapy, Chemokine Therapeutics
    Click to Show/Hide
MOA Agonist
External Link
TTD: D0AZ3Y
 Compound Name MSX-122 Phase 1 [14]
MOA Antagonist
External Link
CID: 11687907
TTD: D0E5JC
DrugBank: DB12715
 Compound Name PF-06747143 Phase 1 [5]
MOA Antagonist
External Link
TTD: D0LC5L
 Compound Name BMS-936564 Phase 1 [15]
MOA Modulator
External Link
TTD: D0Z8JR
 Compound Name LY2624587 Phase 1 [16]
MOA Antagonist
External Link
TTD: D3KZ6M
 Compound Name GMI-1359 Phase 1 [17]
MOA Antagonist
External Link
TTD: DBDW09
 Compound Name Garnocestim Discontinued in Phase 1 [18]
Synonyms
SB-251353
    Click to Show/Hide
MOA Modulator
External Link
TTD: D0H5KK
 Compound Name SURADISTA Discontinued in Phase 1 [19]
Synonyms
PNU-145156E; FCE-26644 (formerly); PNU-151484 (Na salt); 7,7'-[Carbonylbis[imino(1-methyl-1H-pyrrole-4,2-diyl)carbonylimino(1-methyl-1H-pyrrole-4,2-diyl)carbonylimino]]bis-1,3-naphthalenedisulfonic acid tetrapotassium salt; 7,7-Ureylene-bis(1-methyl-4,2-pyrrolecarboxamido)bis(1-methyl-4,2-pyrrolecarboxamido)bis(1,3-naphthalenedisulfonic acid) tetrapotassium salt
    Click to Show/Hide
MOA Modulator
External Link
TTD: D0I4OX
 Compound Name MAb173 Preclinical [20]
MOA Antagonist
External Link
TTD: D2NU0H
 Compound Name KRH-2731 Terminated [21]
MOA Binder
External Link
TTD: D00FJS
 Compound Name Cyclo(-D-Tyr-L-Arg-L-MeArg-L-Nal-Gly-) Investigative [22]
Synonyms
CHEMBL436536
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 99 nM
External Link
CID: 44418888
TTD: D00GII
 Compound Name Cyclo(-D-MeTyr-D-Arg-L-Arg-L-Nal-Gly-) Investigative [22]
Synonyms
CHEMBL375993
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 157 nM
External Link
CID: 44418891
TTD: D00XBM
 Compound Name Cyclo(-D-Tyr-D-MeArg-L-Arg-L-Nal-Gly-) Investigative [22]
Synonyms
CHEMBL218806
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 3 nM
External Link
CID: 44418892
TTD: D02UES
 Compound Name GSK-812397 Investigative [23]
Synonyms
CXCR4 receptor antagonists (HIV-1 infection); CXCR4 receptor antagonists (HIV-1 infection), GlaxoSmithKline
    Click to Show/Hide
MOA Antagonist
Activity IC50 = 0.87 nM
External Link
CID: 11718722
TTD: D03QJA
 Compound Name AT-009 Investigative [23]
MOA Antagonist
External Link
TTD: D04ATE
 Compound Name Cyclo(-D-Tyr-D-Arg-L-Arg-L-MeNal-Gly-) Investigative [22]
Synonyms
CHEMBL426169
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 563 nM
External Link
CID: 44418894
TTD: D04BVW
 Compound Name Cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-L-Ala-) Investigative [22]
Synonyms
CHEMBL387120
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 170 nM
External Link
CID: 44418872
TTD: D04PDF
 Compound Name Cyclo(-D-Tyr-L-MeArg-L-Arg-L-Nal-Gly-) Investigative [22]
Synonyms
CHEMBL374421
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 23 nM
External Link
CID: 44418887
TTD: D04TED
 Compound Name Cyclo(-D-Tyr-Arg-Arg-Nal-Gly-) Investigative [24]
Synonyms
Fc-131; FC131; CHEMBL436283; FC 131; 606968-52-9; CHEMBL2180076; AC1NQNK6; SCHEMBL15987252; ZINC3925712; Cyclo(-Nal-Gly-D-Tyr-Arg-Arg-); BDBM50399002; BDBM50166106; KB-272560; B7647; N-{3-[(2S,5S,8S,14R)-5-(3-Guanidino-propyl)-14-(4-hydroxy-benzyl)-8-naphthalen-2-ylmethyl-3,6,9,12,15-pentaoxo-1,4,7,10,13pentaaza-cyclopentadec-2-yl]-propyl}-guanidine
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 4 nM
External Link
CID: 5275843
TTD: D04TIO
 Compound Name Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-beta-Ala-) Investigative [22]
Synonyms
CHEMBL219135
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 350 nM
External Link
CID: 44418885
TTD: D04XHX
 Compound Name KUR-CXCR4 Investigative [23]
MOA Modulator
External Link
TTD: D05IXH
 Compound Name isothiourea-1t Investigative [25]
Synonyms
IT1t
    Click to Show/Hide
MOA Antagonist
Activity IC50 = 8 nM
External Link
CID: 25147749
TTD: D05VQJ
 Compound Name Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-Sar-) Investigative [22]
Synonyms
CHEMBL374862
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 256 nM
External Link
CID: 44418895
TTD: D05YHT
 Compound Name CX-02 Investigative [23]
Synonyms
CX-05; CXCR4 monoclonal antibodies (cancer); CXCR4 monoclonal antibodies (cancer), Northwest Biotherapeutics; CXCR4 therapeutics (cancer), Northwest Biotherapeutics
    Click to Show/Hide
External Link
TTD: D06EBJ
 Compound Name isothiourea-1a Investigative [25]
Synonyms
IT1a
    Click to Show/Hide
MOA Antagonist
Activity IC50 = 11 nM
External Link
CID: 11176403
TTD: D06MBD
 Compound Name ND-401 Investigative [23]
Synonyms
ND-4019; CCR5 and CXCR4 inhibitors (HIV infection), NeED Pharmaceuticals
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: D07IZP
 Compound Name CXCR4 gene disrupted T cells Investigative [23]
Synonyms
CXCR4 gene disrupted T cells (HIV infection)
    Click to Show/Hide
MOA Modulator
External Link
TTD: D07VDF
 Compound Name T134 Investigative [26]
Synonyms
GTPL852
    Click to Show/Hide
MOA Antagonist
External Link
CID: 16197445
TTD: D08NJD
 Compound Name Cyclo(-D-Tyr-L-Arg-L-Arg-L-Ala-Sar-) Investigative [22]
Synonyms
CHEMBL219075
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 167 nM
External Link
CID: 44418890
TTD: D08XRM
 Compound Name Cyclo(-D-Tyr-D-Arg-L-MeArg-L-Nal-Gly-) Investigative [22]
Synonyms
CHEMBL376219
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 21 nM
External Link
CID: 44418893
TTD: D08YYV
 Compound Name ATI-2341 Investigative [23]
Synonyms
ATI-2346; ATI-2756; ATI-2766; CXCR4 agonists (cancer/bone marrow transplantation), Ascent; Pepducins (cancer/bone marrow transplantation), Ascent
    Click to Show/Hide
MOA Agonist
External Link
CID: 121513892
TTD: D0A7GH
 Compound Name Cyclo(-D-Tyr-L-Arg-L-Arg-L-MeNal-Gly-) Investigative [22]
Synonyms
CHEMBL375850
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 250 nM
External Link
CID: 44418889
TTD: D0B8VW
 Compound Name Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-L-Ala-) Investigative [22]
Synonyms
CHEMBL376811
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 92 nM
External Link
CID: 44418879
TTD: D0BH8K
 Compound Name Cyclo(-D-Tyr-D-Ala-L-Arg-L-Nal-Gly-) Investigative [22]
Synonyms
CHEMBL384429
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 230 nM
External Link
CID: 44418869
TTD: D0FQ3G
 Compound Name T140 Investigative [26]
Synonyms
[L-3-(2-naphthyl)-alanine3]-T134
    Click to Show/Hide
MOA Antagonist
External Link
CID: 16130395
TTD: D0I6AN
 Compound Name Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-D-Ala-) Investigative [22]
Synonyms
CHEMBL373636
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 11 nM
External Link
CID: 44418880
TTD: D0K0SO
 Compound Name Cyclo(-D-Ala-D-Arg-L-Arg-L-Nal-Gly-) Investigative [22]
Synonyms
CHEMBL373440
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 130 nM
External Link
CID: 44418868
TTD: D0K9KQ
 Compound Name CTCE-0324 Investigative [23]
Synonyms
Vascular disease therapeutic, Chemokine Therapeutics
    Click to Show/Hide
MOA Modulator
External Link
TTD: D0L3GH
 Compound Name Cyclo(-D-Tyr-L-Ala-L-Arg-L-Nal-Gly-) Investigative [22]
Synonyms
CHEMBL374108
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 63 nM
External Link
CID: 44418865
TTD: D0M6RQ
 Compound Name Cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-beta-Ala-) Investigative [22]
Synonyms
CHEMBL375991
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 47 nM
External Link
CID: 44418878
TTD: D0P7UV
 Compound Name Cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-Gly-) Investigative [22]
Synonyms
CHEMBL219474
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 4 nM
External Link
CID: 11158428
TTD: D0Q3MM
 Compound Name LP-0067 Investigative [23]
Synonyms
CXCR4 antagonists (autoimmune disease); CXCR4 antagonists (autoimmune disease), Leo Pharma
    Click to Show/Hide
MOA Antagonist
External Link
TTD: D0Q7XS
 Compound Name NB-325 Investigative [23]
Synonyms
PEHMB; Polyethylene hexamethylene biguanide
    Click to Show/Hide
MOA Modulator
External Link
CID: 15954275
TTD: D0R4WT
 Compound Name Cyclo(-D-MeTyr-L-Arg-L-Arg-L-Nal-Gly-) Investigative [22]
Synonyms
CHEMBL219096
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 128 nM
External Link
CID: 44418886
TTD: D0S0GV
 Compound Name Cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-D-Ala-) Investigative [22]
Synonyms
CHEMBL375990
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 11 nM
External Link
CID: 44418873
TTD: D0S0PU
 Compound Name Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-L-Pic-) Investigative [22]
Synonyms
CHEMBL373637
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 640 nM
External Link
CID: 44418883
TTD: D0ST1U
 Compound Name T22 Investigative [26]
Synonyms
[Tyr5,12,Lys7]-polyphemusin II
    Click to Show/Hide
MOA Antagonist
External Link
CID: 16197316
TTD: D0TL6C
 Compound Name TN-14003 Investigative [27]
Synonyms
UNII-1TW3FT746I; 1TW3FT746I; TN14003; BDBM194584; US9205085, MSX-207; H-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-NH2; L-Argininamide, L-arginyl-L-arginyl-3-(2-naphthalenyl)-L-alanyl-L-cysteinyl-L-tyrosyl-N5-(aminocarbonyl)-L-ornithyl-L-lysyl-D-lysyl-L-prolyl-L-tyrosyl-L-arginyl-N5-(aminocarbonyl)-L-ornithyl-L-cysteinyl-, cyclic (4->13)-disulfide
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 16130647
TTD: D0Y3OX
 Compound Name Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-Gly-) Investigative [22]
Synonyms
CHEMBL219339
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 8 nM
External Link
CID: 11331592
TTD: D0ZO3C
 Compound Name CXCL8 Investigative [28]
Synonyms
Interleukin-8; CHEMBL411250; IL-8
    Click to Show/Hide
MOA Agonist
External Link
CID: 74974005
TTD: D07PHS
 Compound Name viral macrophage inflammatory protein-II Investigative [29]
Synonyms
CFLTKRGRQVC; vMIP-II; AC1LAF0N; GTPL768; vMIP-II (RESIDUE 41-51, CYCLIC); (4R,7S,10S,13S,19S,22S,25S,28S,31S,34R)-34-amino-22-(4-aminobutyl)-10-(3-amino-3-oxopropyl)-31-benzyl-13,19-bis[3-(diaminomethylideneamino)propyl]-25-[(1R)-1-hydroxyethyl]-28-(2-methylpropyl)-6,9,12,15,18,21,24,27,30,33-decaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacontane-4-carboxylic acid
    Click to Show/Hide
MOA Antagonist
External Link
CID: 486830
TTD: D09PZD
DNA (cytosine-5)-methyltransferase 1 (DNMT1) 27 Compound(s) Regulating the Target Click to Show/Hide the Full List
 Compound Name SGI110 Phase 3 [30]
MOA Modulator
External Link
CID: 137295284
TTD: D0Q5KZ
 Compound Name Guadecitabine Phase 3 [11]
Synonyms
UNII-2KT4YN1DP7; 929901-49-5; 2KT4YN1DP7; SGI-110 free acid; Guadecitabine [USAN:INN]; GuadecitabineSGI-110; Guadecitabine (USAN/INN); CHEMBL3544916; Guanosine, 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxy-; ZINC43203165; AKOS027321496; AKOS030238181; DB11918; CS-3089; HY-13542; D10877; 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxyguanosine
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 135564655
TTD: D0VZ4N
DrugBank: DB11918
 Compound Name CC-486 Phase 3 [31]
Synonyms
AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 9840076
TTD: D09NTC
 Compound Name S-110 Phase 3 [32]
Synonyms
DNA demethylating agent (myelodysplastic syndrome), Supergen
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: D0A2BO
 Compound Name Palifosfamide Phase 2 [33]
Synonyms
ZIO-201
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 100427
TTD: D04FDN
DrugBank: DB05668
 Compound Name RX-3117 Phase 2 [34]
Synonyms
Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11242315
TTD: D0L7WS
 Compound Name Antroquinonol Phase 2 [35]
Synonyms
Hocena; Fungal extract (cancer), Golden Biotechnology
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 24875259
TTD: D0T3AW
DrugBank: DB12326
 Compound Name GSK4172239 Phase 1 [36]
MOA Inhibitor
External Link
TTD: D5QR2M
 Compound Name PMID27376512-Compound-miR-155-5p Patented [37]
MOA Inhibitor
Activity Ki = 27.88 nM
External Link
TTD: D01CGQ
 Compound Name PMID27376512-Compound-Table1Example11 Patented [37]
MOA Inhibitor
Activity IC50 = 39440 nM
External Link
CID: 75201485
TTD: D04JIH
 Compound Name PMID27376512-Compound-Table1Example16 Patented [37]
MOA Inhibitor
Activity IC50 = 22520 nM
External Link
CID: 75201537
TTD: D05DSL
 Compound Name PMID27376512-Compound-Table1Example5 Patented [37]
MOA Inhibitor
Activity IC50(DNMT1) = 3530 nM
External Link
CID: 73774653
TTD: D09FMS
 Compound Name PMID27376512-Compound-asCEBP-2HPE Patented [37]
MOA Inhibitor
Activity Ki = 135.2 nM
External Link
TTD: D0E7OA
 Compound Name PMID27376512-Compound-asCEBP-1 Patented [37]
MOA Inhibitor
Activity Ki = 2003 nM
External Link
TTD: D0G6ON
 Compound Name PMID27376512-Compound-Table1Example4 Patented [37]
MOA Inhibitor
Activity IC50 = 13810 nM
External Link
CID: 75201432
TTD: D0K4YF
 Compound Name PMID27376512-Compound-asCEBP-2 Patented [37]
MOA Inhibitor
Activity Ki = 434.1 nM
External Link
TTD: D0KE4E
 Compound Name PMID27376512-Compound-asCEBP-1HPE Patented [37]
MOA Inhibitor
Activity Ki = 917.5 nM
External Link
TTD: D0LK4R
 Compound Name PMID27376512-Compound-Table1Example8 Patented [37]
MOA Inhibitor
Activity IC50 = 6850 nM
External Link
CID: 75201482
TTD: D0RT6C
 Compound Name PMID27376512-Compound-MTC-433 Patented [37]
MOA Inhibitor
Activity IC50 = 4.22 nM
External Link
TTD: D0U5CK
 Compound Name PMID27376512-Compound-Table1Example30 Patented [37]
MOA Inhibitor
External Link
CID: 75201638
TTD: D0YK6K
 Compound Name PMID27376512-Compound-MTC-424 Patented [37]
MOA Inhibitor
Activity IC50 = 1940 nM
External Link
TTD: D02WRM
 Compound Name PMID27376512-Compound-MTC-427 Patented [37]
MOA Inhibitor
Activity IC50 = 295 nM
External Link
TTD: D0HA0J
 Compound Name PMID27376512-Compound-MTC-422 Patented [37]
MOA Inhibitor
Activity IC50 = 1430 nM
External Link
TTD: D0QY0N
 Compound Name PMID27376512-Compound-MTC-423 Patented [37]
MOA Inhibitor
Activity IC50 = 363 nM
External Link
TTD: D0W9VZ
 Compound Name PMX-700 Investigative [38]
Synonyms
SJ-005019; SJ-005059; DC-010-116; Temozolomide analogs (cancer), Pharminox
    Click to Show/Hide
MOA Modulator
External Link
TTD: D03DTQ
 Compound Name XB-05 Investigative [38]
MOA Inhibitor
External Link
TTD: D0JV8Q
 Compound Name CP-4200 Investigative [38]
Synonyms
Lipidated azacitidine (cancer, Lipid Vector), Clavis Pharma; 5-azacytidine-5'-elaidate
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: D0OT1S
2C60: Breast cancer 2 Compound(s) Regulating the Disease Click to Show/Hide the Full List
 Compound Name Entrectinib Approved [39]
Synonyms
1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK
    Click to Show/Hide
External Link
CID: 25141092
TTD: D0O0LS
DrugBank: DB11986
 Compound Name Everolimus Approved [40]
External Link
CID: 6442177
TTD: D09ZSC
DrugBank: DB01590
References
Ref 1 LncRNA UCA1 promotes SOX12 expression in breast cancer by regulating m(6)A modification of miR-375 by METTL14 through DNA methylation. Cancer Gene Ther. 2022 Jul;29(7):1043-1055. doi: 10.1038/s41417-021-00390-w. Epub 2022 Jan 13.
Ref 2 LNC942 promoting METTL14-mediated m(6)A methylation in breast cancer cell proliferation and progression. Oncogene. 2020 Jul;39(31):5358-5372. doi: 10.1038/s41388-020-1338-9. Epub 2020 Jun 23.
Ref 3 Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127. doi: 10.1517/14728210802676278.
Ref 4 FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 217159
Ref 5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 6 Anti-ageing pipeline starts to mature. Nat Rev Drug Discov. 2018 Sep;17(9):609-612. doi: 10.1038/nrd.2018.134. Epub 2018 Aug 3.
Ref 7 Pharmacokinetic effect of AMD070, an Oral CXCR4 antagonist, on CYP3A4 and CYP2D6 substrates midazolam and dextromethorphan in healthy volunteers. J Acquir Immune Defic Syndr. 2008 Apr 15;47(5):559-65. doi: 10.1097/QAI.0b013e3181627566.
Ref 8 CXCR4 Antagonist TG-0054 Mobilizes Mesenchymal Stem Cells, Attenuates Inflammation, and Preserves Cardiac Systolic Function in a Porcine Model of Myocardial Infarction. Cell Transplant. 2015;24(7):1313-28. doi: 10.3727/096368914X681739. Epub 2014 May 12.
Ref 9 CXCR4 inhibitors: tumor vasculature and therapeutic challenges. Recent Pat Anticancer Drug Discov. 2012 Sep;7(3):251-64. doi: 10.2174/157489212801820039.
Ref 10 A CXCR4 antagonist CTCE-9908 inhibits primary tumor growth and metastasis of breast cancer. J Surg Res. 2009 Aug;155(2):231-6. doi: 10.1016/j.jss.2008.06.044. Epub 2008 Aug 9.
Ref 11 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 12 Therapeutic antibodies directed at G protein-coupled receptors. MAbs. 2010 Nov-Dec; 2(6): 594-606.
Ref 13 Beneficial effect of a CXCR4 agonist in murine models of systemic inflammation. Inflammation. 2012 Feb;35(1):130-7. doi: 10.1007/s10753-011-9297-5.
Ref 14 Comparative evaluation of CC chemokine-induced migration of murine CD8alpha+ and CD8alpha- dendritic cells and their in vivo trafficking. J Leukoc Biol. 2004 Feb;75(2):275-85. doi: 10.1189/jlb.1202613. Epub 2003 Nov 3.
Ref 15 BMS-936564/MDX-1338: a fully human anti-CXCR4 antibody induces apoptosis in vitro and shows antitumor activity in vivo in hematologic malignancies. Clin Cancer Res. 2013 Jan 15;19(2):357-66. doi: 10.1158/1078-0432.CCR-12-2333. Epub 2012 Dec 4.
Ref 16 Inhibition of CXCR4 by LY2624587, a Fully Humanized Anti-CXCR4 Antibody Induces Apoptosis of Hematologic Malignancies. PLoS One. 2016 Mar 8;11(3):e0150585. doi: 10.1371/journal.pone.0150585. eCollection 2016.
Ref 17 Clinical pipeline report, company report or official report of GlycoMimetics.
Ref 18 CN patent application no. 101094684, With the combination of chemokine activation progenitor cells/stem cells.
Ref 19 Suradista NSC 651016 inhibits the angiogenic activity of CXCL12-stromal cell-derived factor 1alpha. Clin Cancer Res. 2002 Dec;8(12):3955-60.
Ref 20 Caspase-dependent apoptosis of cells expressing the chemokine receptor CXCR4 is induced by cell membrane-associated human immunodeficiency virus type 1 envelope glycoprotein (gp120). Virology. 2000 Mar 15;268(2):329-44. doi: 10.1006/viro.1999.0151.
Ref 21 Progress in targeting HIV-1 entry. Drug Discov Today. 2005 Aug 15;10(16):1085-94. doi: 10.1016/S1359-6446(05)03550-6.
Ref 22 Structure-activity relationships of cyclic peptide-based chemokine receptor CXCR4 antagonists: disclosing the importance of side-chain and backbone functionalities. J Med Chem. 2007 Jan 25;50(2):192-8. doi: 10.1021/jm0607350.
Ref 23 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 71).
Ref 24 Identification of novel non-peptide CXCR4 antagonists by ligand-based design approach. Bioorg Med Chem Lett. 2008 Jul 15;18(14):4124-9. doi: 10.1016/j.bmcl.2008.05.092. Epub 2008 May 29.
Ref 25 Orally bioavailable isothioureas block function of the chemokine receptor CXCR4 in vitro and in vivo. J Med Chem. 2008 Dec 25;51(24):7915-20. doi: 10.1021/jm801065q.
Ref 26 A low-molecular-weight inhibitor against the chemokine receptor CXCR4: a strong anti-HIV peptide T140. Biochem Biophys Res Commun. 1998 Dec 30;253(3):877-82. doi: 10.1006/bbrc.1998.9871.
Ref 27 Discovery of small molecule CXCR4 antagonists. J Med Chem. 2007 Nov 15;50(23):5655-64. doi: 10.1021/jm070679i. Epub 2007 Oct 24.
Ref 28 Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion injury. Proc Natl Acad Sci U S A. 2004 Aug 10;101(32):11791-6. doi: 10.1073/pnas.0402090101. Epub 2004 Jul 28.
Ref 29 A broad-spectrum chemokine antagonist encoded by Kaposi's sarcoma-associated herpesvirus. Science. 1997 Sep 12;277(5332):1656-9. doi: 10.1126/science.277.5332.1656.
Ref 30 Immunomodulatory action of the DNA methyltransferase inhibitor SGI-110 in epithelial ovarian cancer cells and xenografts. Epigenetics. 2015;10(3):237-46.
Ref 31 Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes. Leukemia. 2016 Apr;30(4):889-96.
Ref 32 S110, a 5-Aza-2'-deoxycytidine-containing dinucleotide, is an effective DNA methylation inhibitor in vivo and can reduce tumor growth. Mol Cancer Ther. 2010 May;9(5):1443-50.
Ref 33 Anticancer activity of stabilized palifosfamide in vivo: schedule effects, oral bioavailability, and enhanced activity with docetaxel and doxorubicin. Anticancer Drugs. 2012 Feb;23(2):173-84.
Ref 34 Metabolism, mechanism of action and sensitivity profile of fluorocyclopentenylcytosine (RX-3117; TV-1360). Invest New Drugs. 2013 Dec;31(6):1444-57.
Ref 35 Antroquinonol D, isolated from Antrodia camphorata, with DNA demethylation and anticancer potential. J Agric Food Chem. 2014 Jun 18;62(24):5625-35.
Ref 36 Clinical pipeline report, company report or official report of GlaxoSmithKline
Ref 37 DNA methyltransferase inhibitors: an updated patent review (2012-2015). Expert Opin Ther Pat. 2016 Sep;26(9):1017-30. doi: 10.1080/13543776.2016.1209488. Epub 2016 Jul 18.
Ref 38 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2605).
Ref 39 Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372... Cancer Discov. 2017 Apr;7(4):400-409.
Ref 40 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015